The favorable outcomes of PFT treatment were comparable to those of simvastatin, which diminished the expression of phosphorylated tau by 45.9%, ERK1/2 by 69.1%, p38-MAPK by 68.8%, GSK-3β by 69.2%, and mTOR by 43.4% in AD mice. This evidence concerns the gene MAPK14 and Alzheimer disease.